Skip to content

Medical-device intelligence

QAZ: Cancer Predisposition Risk Assessment System

FDA product code QAZ: Cancer Predisposition Risk Assessment System. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
QAZ
FDA device name
Cancer Predisposition Risk Assessment System
Device class
2
Regulation number
866.6090
Medical specialty
Medical Genetics
Review panel
PA

FDA definition

A qualitative in vitro molecular diagnostic system used for the detection of select variants in specified cancer-related genes. The device is intended to be used on genomic DNA isolated from human specimens collected by the user. The results of the test provide users with a genetic health risk assessment for developing certain cancers. The test may not include all variants associated with a predisposition of developing cancer and is not intended to describe a person’s overall risk of developing any type of cancer nor to aid in determination of treatment or act as a substitute for recommended cancer screenings or appropriate follow-up. The device is for over-the-counter use.
Explore medical genetics records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

3 clearance records and 0 recall records in the covered releases, across 1 source company names and 1 product codes. Dated history runs from Jan 18, 2019 to Aug 31, 2023.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202600
September 202600
October 202600

Product codes represented

Code and FDA device nameClearancesRecalls
QAZ · Cancer Predisposition Risk Assessment System30

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

3 matching records
Device / recordCompany in FDA recordSourceSource date
23andMe® Personal Genome Service® (PGS®) Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)K223597 · QAZ23AndMe, Inc.510(k)Aug 31, 2023FDA decision date
23andMe PGS Genetic Risk Report for Hereditary Prostate Cancer (HOXB13-Related)K211499 · QAZ23AndMe, Inc.510(k)Jan 6, 2022FDA decision date
MUTYH-Associated Polyposis (MAP)K182784 · QAZ23AndMe, Inc.510(k)Jan 18, 2019FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗